Lupin Launches Sildenafil for Oral Suspension in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Sildenafil for Oral Suspension, 10 mg/mL, having received an approval from the United States Food and Drug Administration (FDA).

Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio® for Oral Suspension, 10 mg/mL of Viatris Specialty LLC.

Sildenafil for Oral Suspension (RLD Revatio®) had estimated annual sales of USD 64 million in the U.S. (IQVIA MAT July 2022).

Source : Equity Bulls

Keywords

Lupin ProductLaunch SildenafilforOralSuspension Approval USFDA